Restless legs syndrome (RLS)
Horizant® (gabapentin enacarbil) extended-release tablets
INDICATIONS AND USAGE HORIZANT is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. USE IN SPECIFIC POPULATIONS DOSAGE AND ADMINISTRATION If the dose is not taken at the recommended time, the next dose should be taken the following day as prescribed. Tablets should be swallowed whole and should not be cut, crushed, or chewed. Renal Impairment and Hemodialysis In patients with stable renal function, CrCl can be estimated using the equation of Cockcroft and Gault: for males: CrCl = (140-age)(weight) / [(72)(SCr)] for females: CrCl = (0.85)(140-age)(weight) / [(72)(SCr)] where age is in years, weight is in kilograms, and SCr is serum creatinine in mg/dL. HORIZANT is not recommended for use in patients with a CrCl <30 mL/min or on hemodialysis because the dose cannot be reduced below 600 mg. HOW SUPPLIED NDC 0173-0806-01: Bottles of 30 |
Reference(s)
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.